News & Updates
Filter by Specialty:

Inhaled amikacin cuts VAP burden in mechanically ventilated patients
16 Jan 2024
byAudrey Abella
In critically ill patients who have been on invasive mechanical ventilation (IMV) for at least 3 days, a subsequent 3-day course of preventive inhaled amikacin reduced the burden of ventilator-associated pneumonia (VAP) during 28 days of follow-up, findings from the AMIKINHAL trial have shown.